Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential for NKTR-181 as a potentially new opioid therapy with reduced abuse potential, and the value and potential of our technology and drug candidates in our research and development pipeline.  Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) NKTR-181 is in the earlier stages of clinical development and could fail at any time due to numerous unpredictable and significant risks related to safety, efficacy and other important findings that can negatively impact clinical development; (ii) although we have conducted various experiments using laboratory and home-based chemistry techniques that have so far been unable to convert NKTR-181 into a rapid-acting, more abusable opioid, it is possible that an alternative chemistry technique or process may be discovered in the future that would enable the conversion of NKTR-181 into a more abusable opi
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
(Date:9/18/2014)... , Sept. 18, 2014 Just days before ... a three-day quarantine to contain the spread of Ebola, World ... medical relief supplies – thanks to private donations. ... United States , through its affiliate McKesson Medical-Surgical donated ... the entire country of Sierra Leone,s ...
(Date:9/17/2014)... Sept. 17, 2014 North America Gynecological ... GlobalData,s new report, "North America ... market data on the North America Gynecological Devices ... US dollars, volume (in units) and average prices ... Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3
... Bias, DURHAM, N.C., Sept. 15 Less ... treatment are eventually published in,medical journals, according to ... Oncologist.", (LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ), ... of Washington and,Fred Hutchinson Cancer Research Center, Seattle, ...
... a novel ... macrolide-related drug class, WATERTOWN, Mass., Sept. ... molecule anti-infective drugs, announced,today the initiation of a Phase 1 ... novel,macrolide-related drug class with a distinct resistance profile. The,clinical development ...
Cached Medicine Technology:Most Cancer Treatment Studies Aren't Published, Study Finds 2Most Cancer Treatment Studies Aren't Published, Study Finds 3Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 2Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 3
(Date:9/18/2014)... 2014 Pathways Home Health & ... position of Chief Medical Director. Prior to accepting ... Pathways programs including Pathways KIDS, adult palliative care, and ... and Santa Clara Counties. , In her new ... Pathway’s patient care program. She will supervise five medical ...
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Imaging technology has ... stress disorder (PTSD) manifest in the brain, according to ... health condition that can cause a wide range of ... being in a constant state of stress and avoiding ... the study. Researchers identified a specific opioid receptor ...
(Date:9/18/2014)... 2014 -- Only about half of all pregnant women ... thousands of moms-to-be and their babies at increased risk of ... be a routine part of prenatal care," said Edward McCabe, ... should offer their pregnant patients a flu shot each year ... , A report by the U.S. Centers for Disease Control ...
(Date:9/18/2014)... in disadvantaged neighborhoods have worse musculoskeletal pain outcomes ... vehicle collision than individuals from higher socioeconomic status ... as age, sex, income, education, and employment status. ... research study led by Samuel McLean, MD, MPH, ... the University of North Carolina School of Medicine. ...
(Date:9/18/2014)... COPENHAGEN, Denmark and CAMBRIDGE, Massachusetts, U.S.A., September 18, ... Tech) is providing sequencing service to Denmark-based DLF-Trifolium ... (MBG) at Aarhus University in an effort to ... varieties by employing genomic selection (GS) methods. , ... selection, which in contrast to the traditional QTL-based ...
Breaking Medicine News(10 mins):Health News:Dr. Ellen Brown Promoted to Chief Medical Director at Pathways Home Health & Hospice 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 3Health News:Flu vaccine for expectant moms a top priority 2Health News:Living in a disadvantaged neighborhood worsens musculoskeletal pain outcomes after trauma 2Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2
... representing the Women,s Dermatologic Society (WDS) will, help Texan ... skin cancer screenings and sun safety tips ... Texas, Sept. 18 Even though higher altitudes,mean heightened ... enjoying the upcoming Plano Hot Air Balloon Festival will ...
... cells and other tissue in the laboratory in conditions similar ... , The technology, developed and patented by scientists at Durham ... scaffold which allows cells to be grown in a more ... of a Petri dish. , Evidence gathered by the ...
... that training programs for females to restore balance between ... could help reduce the disproportionately high number of ACL ... shows that the amount of preparatory muscle action in ... is associated with knee positions that are considered at ...
... for Treating Major Symptoms of Lumbar ... ... KYPH ) today announced that Dr. Michael Marks, orthopaedic spine,surgeon from ... will be interviewed together on,American Health Radio, the nationally-syndicated health radio ...
... 18 AMERIGROUP,Corporation (NYSE: AGP ) today ... Centers for Medicaid and Medicare Services (CMS) to ... traditional Medicare,Advantage health plans to address the specialized ... states. AMERIGROUP currently coordinates care for approximately ...
... heard,arguments yesterday in the lawsuit brought in Superior Court ... time during the,U.S. Medical Licensing Examination (USMLE). "Fairness ... remain the,overriding concerns of the exam,s sponsors," said Joseph ... Examiners, which co-sponsors the,exam and was named in the ...
Cached Medicine News:Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 2Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 3Health News:Cell growth technology promises more successful drug development 2Health News:Cell growth technology promises more successful drug development 3Health News:Muscle patterns in women may be linked to at risk positioning for ACL tears 2Health News:Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007 2Health News:Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007 3Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 2Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 3Health News:Massachusetts State Court Hears Suit by Breastfeeding Mother on Medical Licensing Exam 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... ADx pacemaker family, which ... dual-chamber pacemaker, provides clinicians ... including the revolutionary AF ... U.S. commercially approved algorithm ...
... ADx pacemaker family, which includes ... provides clinicians with the most ... the revolutionary AF Suppression™ algorithm, ... commercially approved algorithm designed to ...
Medicine Products: